Olive Garden rolled out a "Lighter Portions" menu — seven smaller-size versions of core entrées, priced at $12.99 to $13.99 — to all of its U.S. locations by the end of January 2026, joining Cheesecake Factory, Chipotle, Subway, and a long list of smaller chains in redesigning portions for the roughly 12 percent of American adults now taking a GLP-1 drug. [1] The mechanics are consistent: smaller entrée sizes, higher protein share, vegetable-forward preparations, and prices that do not fall in proportion with the portions. A 42-ounce bowl of fettuccine is not the anchor. A 9-ounce bowl with grilled chicken is.

The restaurant business has been building toward this for two years. Industry analysts have reported that GLP-1 users reduce caloric intake at restaurants meaningfully while visiting nearly as often. [2] That math is devastating to the model that Olive Garden helped establish in the 1990s — unlimited breadsticks, endless soup and salad, the second plate as a bragging right. [3] The chain is not walking away from abundance. It is adding a lane for the customer who does not want it.

The X reading is less flattering than the trade press. Food writers post side-by-side photos of the "small-at-premium" plate and call it an airline-food con. [4] Restaurant line cooks, on TikTok and X, post about upselling regulars they know are on Ozempic — an awkward transaction because the upsell no longer lands and the customer is buying restraint from the place that used to sell the opposite. CAVA, the fast-casual winner of the early GLP-1 era, has moved in the same direction without renaming the menu.

The national dining motif since 1990 was the super-size. A Danish injectable is reversing it.

-- NORA WHITFIELD, Chicago